Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Intellia Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$346.64M. For fiscal 2025 it was -$394.74M. The highest annual figure on record is $36.11M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$394.74M | – |
| FY2024 | Dec 31, 2024 | -$348.88M | – |
| FY2023 | Dec 31, 2023 | -$394.09M | – |
| FY2022 | Dec 31, 2022 | -$333.29M | – |
| FY2021 | Dec 31, 2021 | -$225.03M | – |
| FY2020 | Dec 31, 2020 | -$49.91M | – |
| FY2019 | Dec 31, 2019 | -$103.24M | – |
| FY2018 | Dec 31, 2018 | -$61.26M | – |
| FY2017 | Dec 31, 2017 | -$65.28M | -280.8% |
| FY2016 | Dec 31, 2016 | $36.11M | – |
| FY2015 | Dec 31, 2015 | -$1.76M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$83.11M | – |
| Q1 FY2026 | Mar 31, 2026 | -$117.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$76.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$99.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$148.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$85.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$84.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$58.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$120.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$93.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$101.38M | – |
| Q2 FY2023 | Jun 30, 2023 | -$90.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$109.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$89.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$78.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$85.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$79.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$54.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$65.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$52.98M | -192.3% |
| Q1 FY2021 | Mar 31, 2021 | -$52.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$40.23M | – |
| Q3 FY2020 | Sep 30, 2020 | -$28.56M | – |
| Q2 FY2020 | Jun 30, 2020 | $57.42M | – |
| Q1 FY2020 | Mar 31, 2020 | -$38.55M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.66M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$27.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$21.45M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.54M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.45M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.50M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.31M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.89M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.68M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$14.41M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.61M | – |
See a number that looks wrong?